J 2024

Diabetes mellitus in stable chronic heart failure and the combination with humoral activation, their association, and prediction of 2-year adverse outcomes. Data from the FAR NHL registry

LÁBR, Karel, Jindřich ŠPINAR, Jiří PAŘENICA, Lenka ŠPINAROVÁ, Jan KREJČÍ et. al.

Basic information

Original name

Diabetes mellitus in stable chronic heart failure and the combination with humoral activation, their association, and prediction of 2-year adverse outcomes. Data from the FAR NHL registry

Authors

LÁBR, Karel (203 Czech Republic, belonging to the institution), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), Lenka ŠPINAROVÁ (203 Czech Republic, belonging to the institution), Jan KREJČÍ (203 Czech Republic, belonging to the institution), Filip MALEK (203 Czech Republic), Petr OSTADAL (203 Czech Republic), Ondřej LUDKA (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution), Růžena LÁBROVÁ (203 Czech Republic, belonging to the institution) and Monika ŠPINAROVÁ (203 Czech Republic, belonging to the institution)

Edition

JOURNAL OF DIABETES, PEOPLES R CHINA, WILEY, 2024, 1753-0393

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 4.500 in 2022

Organization unit

Faculty of Medicine

UT WoS

001310603500001

Keywords in English

chronic heart failure; diabetes mellitus; N-terminal pro-brain natriuretic peptide; prognosis

Tags

International impact, Reviewed
Změněno: 23/9/2024 12:32, Mgr. Tereza Miškechová

Abstract

V originále

Background/Aim: The study aims to describe the role of diabetes in patients with heart failure. Methods: In all, 1052 chronic heart failure patients were included in the FARmacology and NeuroHumoral Activation (FAR NHL) multicenter prospective registry. They had ejection fraction below 50% and were on stable medication for at least 1 month. Results: More than one-third (38.9%) of the patients had diabetes mellitus (DM). Diabetic patients (N N = 409) were older (median 67 vs. 64, p < 0.001), had higher body mass index (BMI) (30 vs. 28 kg/m(2), p < 0.001), much more frequently had ischemic heart disease (71 vs. 47%, p < 0.001), hypertension (80 vs. 67%, p < 0.001), dyslipidemia (89 vs. 69%, p < 0.001), worse renal function (estimated glomerular filtration rate [eGFR] median 63 vs. 73 mL/min/ 1.73 m(2), p < 0.001), and higher N-terminal pro-brain natriuretic peptide (NTproBNP) (median 681 vs. 463 pg/mL, p = 0.003). All-cause death, left ventricle assist device implantation, and orthotopic heart transplantation were set as the combined primary end point, which was present in 15.5% (163 patients) within the 2-year follow-up. In the 2-year follow-up, 81.0% of patients with diabetes survived without a primary end point, while 85.4% of the patients without diabetes survived, the difference being on the verge of statistical significance (p = 0.089). DM is a statistically significant predictor of NT-proBNP value in univariate analysis, but it is not an independent predictor in a multivariate analysis. When the NT-proBNP level was high, the presence of DM did not influence the prognosis. Conclusion: The combination of diabetes and NT-proBNP levels may better stratify the prognosis of patients with chronic heart failure.